Elevance Health (NYSE:ELV) Bolsa

ELEVANCE HEALTH INC

Elevance Health

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Elevance Health Inc

Electrovaya Inc

Evolva Holding SA

Evolva Holding SA ADR

ELVICTOR GROUP INC by Elvictor Group, Inc

Elvictor Group Inc

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics Inc

ELEVATE URANIUM LTD by Elevate Uranium Ltd.

Elevate Uranium Ltd

EVOLVA HLDG AG S/ADR by Evolva Holding AG

News

General

YCBD

cbdMD Announces Distribution Agreement for Statewide Launch in Alabama and Select Markets In The Florida Panhandle

Trading Ideas

ZVSA

ZyVersa Therapeutics Shares Resumed Trade

FATN

FatPipe Shares Halted On Circuit Breaker To The Upside At $12.16/Share

Short Sellers

KRMN

Watching Karman; Shares See Volume To The Downside, Herb Greenberg Issues Report On The Company

Keybanc analyst Jeffrey Hammond maintains nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) with a Overweight and lowers the price target from $75 to $60.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on nVent Electric, Lowers Price Target to $60

JP Morgan analyst Richard Shane maintains NMI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) with a Overweight and lowers the price target from $42 to $41.

NMIH

JP Morgan Maintains Overweight on NMI Holdings, Lowers Price Target to $41

Real estate investor Grant Cardone is doubling down on his support for President Donald Trump's economic policies, claiming they're fixing the country and creating a golden opportunity for real estate investors.
With recent moves on tariffs and a <a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck">drop in interest rates</a>, Cardone believes now is the time for Americans to put their money into real estate and back the president&#8217;s vision.
&#8220;Lower rates, fair trade&#8221;
In a <a href="https://x.com/GrantCardone/status/1907993458687549892">post</a> shared on X, Cardone wrote:&nbsp;
&#8220;President Trump is fixing America &#8211;&nbsp;
• Lower rates&nbsp;
• Fair trade not free trade.&nbsp;
Trust the President. Invest in real estate. Invest in America.&#8221;
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a></li>
</ul>
Along with the post, Cardone shared a chart showing the U.S. 10-year Treasury yield dipping below 4% for the first time since October. Treasury yields have been falling sharply in recent days, reflecting growing investor uncertainty following Trump's rollout of his new &#8220;reciprocal tariff&#8221; policy.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">President Trump is fixing America &#8211; • Lower rates • Fair trade not free trade. Trust the President Invest in real estate &#x1f3e1; Invest in America &#x1f1fa;&#x1f1f8; <a href="https://t.co/yBHkNfPy69">pic.twitter.com/yBHkNfPy69</a>
&mdash; Grant Cardone (@GrantCardone) <a href="https://twitter.com/GrantCardone/status/1907993458687549892?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Market shakes after tariff move
Trump&#8217;s plan imposes a <a href="https://in.benzinga.com/news/global/25/04/44632479/retail-stocks-slammed-as-trumps-tariff-plan-sends-shockwaves-through-sector">baseline 10% tariff on imports</a> from more than 180 countries, sparking a global market reaction. As of Friday morning, the 10-year Treasury yield dropped over 10 basis points to 3.947%, its lowest level since October. The two-year yield also slid to 3.641%.
Investors are now weighing the broader economic impact of these tariffs and watching for clues in Friday's upcoming jobs report. Analysts are concerned that the new trade policy could slow growth.
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
Jim Cramer calls it a &#8220;manmade disaster&#8221;
Not everyone shares Cardone's optimism. CNBC&#8217;s Jim Cramer, who has previously described himself as &#8220;pro-tariff,&#8221; <a href="https://www.benzinga.com/25/04/44642302/jim-cramer-slams-trumps-new-tariffs-despite-calling-himself-pro-tariff-labels-it-a-manmade-disaster">blasted the policy</a> in a CNN <a href="https://www.youtube.com/watch?v=xLNdq907dfI">interview</a>.
&#8220;Let&#8217;s get one thing straight: I&#8217;ve never been a free trader. Never. I&#8217;m a fair trader,&#8221; Cramer said. But he argued that what the country got instead was a &#8220;mess&#8221; — unbalanced tariffs, job losses in small towns, and a stock market downturn.
He said the promised reciprocal trade hasn&#8217;t materialized and criticized the math behind the tariffs as &#8220;ridiculous.&#8221; Cramer also warned that pensions have been hit and people have been left &#8220;in the lurch.&#8221;
See Also: <a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a>
<h2 class="wp-block-heading">Split Reactions&nbsp;</h2>
While Cardone urges Americans to trust Trump and &#8220;invest in America,&#8221; others like Cramer are questioning whether the economic pain is worth it. Still, some on Wall Street see long-term potential.
JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) analyst Thomas Kennedy told <a href="https://www.youtube.com/watch?v=EixgvBh90as">CNBC</a>, &#8220;&#8230;there will be a re-industrialization of America and that has real estate implications,&#8221; suggesting the tariffs could reshape the economy over time.
For now, though, the markets are reacting to uncertainty — and the divide between optimists like Cardone and critics like Cramer is growing wider.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

'President Trump Is Fixing America,' Grant Cardone Says, Wants You To 'Invest In Real Estate, Invest In America'

Keybanc analyst Jeffrey Hammond maintains Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) with a Overweight and lowers the price target from $230 to $190.

Keybanc Maintains Overweight on Enpro, Lowers Price Target to $190

JP Morgan analyst Richard Shane maintains Oportun Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) with a Neutral and lowers the price target from $6.5 to $5.

OPRT

JP Morgan Maintains Neutral on Oportun Financial, Lowers Price Target to $5

WIIM

YYGH

YY Group Holding Limited shares are trading lower. The company reported FY24 revenue results.

Keybanc analyst Jeffrey Hammond maintains Nordson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) with a Overweight and lowers the price target from $260 to $230.

NDSN

Keybanc Maintains Overweight on Nordson, Lowers Price Target to $230

CLNN

Clene shares are trading higher. HC Wainwright & Co. and D. Boral Capital reiterated Buy ratings on the stock.

ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 207.6

Keybanc analyst Jeffrey Hammond maintains Middleby (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) with a Overweight and lowers the price target from $185 to $175.

MIDD

Keybanc Maintains Overweight on Middleby, Lowers Price Target to $175

JP Morgan analyst Richard Shane maintains OneMain Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) with a Overweight and lowers the price target from $58 to $46.

JP Morgan Maintains Overweight on OneMain Holdings, Lowers Price Target to $46

<h2><a href="https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda">[2025-04-08] Hearing: The President's 2025 Trade Policy Agenda &#x7C; The United States Senate Committee on Finance</a> &nbsp;</h2>

Macro Economic Events

Politics

Global

Economics

U.S. Trade Representative Jamieson Greer Says Too Many Countries Are Dependent On Exports To The U.S

APDN

Applied DNA Sciences shares are trading higher after the company announced it regained compliance with Nasdaq regarding its minimum bid price requirement.

JP Morgan analyst Richard Shane maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Neutral and lowers the price target from $30 to $27.

JP Morgan Maintains Neutral on SLM, Lowers Price Target to $27

Keybanc analyst Jeffrey Hammond maintains Janus Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) with a Overweight and lowers the price target from $11 to $9.

Keybanc Maintains Overweight on Janus Intl Gr, Lowers Price Target to $9

<a href="https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda" title="https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda">https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda</a>

U.S. Trade Representative Jamieson Greer Says Any Future Trade Agreements Will Need To Have Strong Rules To Avoid Third Countries Like China From Taking Advantage Of Them; Port Fees On Chinese Ships Are Not All Going To Be Implemented, They Are Not All Going To Be Stacked

Press Releases

Elevance Health Announces Appearance at UBS Global Healthcare Conference

Legal

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

AM Best Affirms Credit Ratings of Elevance Health, Inc. and Its Subsidiaries

Robbins LLP Informs Elevance Health Inc. Stockholders that it is Investigating the Officers and Directors of ELV to Determine if They Breached Fiduciary Duties Owed to Shareholders

Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2024 Results on January 23, 2025

Mark Farrah Associates Delves into Acquisition Impacts Utilizing New Tools

Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

HealthEquity

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

Comments

Elevance Health

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL